Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
Open accessPublished version of a preprint
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Ex vivo systems that incorporate features of the tumor microenvironment and model the dynamic response to immune checkpoint blockade (ICB) may facilitate efforts in precision immuno-oncology and the development of effective combination therapies. Here, we demonstrate the ability to interrogate ex vivo response to ICB using murine- and patient-derived organotypic tumor spheroids (MDOTS/PDOTS). MDOTS/PDOTS isolated from mouse and human tumors retain autologous lymphoid and myeloid cell populations and respond to ICB in short-term three-dimensional microfluidic culture. Response and resistance to ICB was recapitulated using MDOTS derived from established immunocompetent mouse tumor models. MDOTS profiling demonstrated that TBK1/IKKϵ inhibition enhanced response to PD-1 blockade, which effectively predicted tumor response in vivo. Systematic profiling of secreted cytokines in PDOTS captured key features associated with response and resistance to PD-1 blockade. Thus, MDOTS/PDOTS profiling represents a novel platform to evaluate ICB using established murine models as well as clinically relevant patient specimens. Significance: Resistance to PD-1 blockade remains a challenge for many patients, and biomarkers to guide treatment are lacking. Here, we demonstrate feasibility of ex vivo profiling of PD-1 blockade to interrogate the tumor immune microenvironment, develop therapeutic combinations, and facilitate precision immuno-oncology efforts. Cancer Discov; 8(2); 196–215. ©2017 AACR. See related commentary by Balko and Sosman, p. 143. See related article by Deng et al., p. 216. This article is highlighted in the In This Issue feature, p. 127
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We did not observe an effect of IgG4 antibody control (Extended Data Fig. 2b), consistent with previous reports 14,19 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Ex vivo profiling using murine-derived organotypic tumour spheroids (MDOTS) 14 derived from untreated mice bearing B16-ova tumours confirmed enhanced response to anti-PD-1 plus TBK1i (Fig. 1e).”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“and that disrupting TBK1 signaling has shown early promise enhancing response to ICB in murine tumour models 14,15 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944 · cited 1×
“Although reported sources of CCL19 and CXCL13 include stromal, immune, and tumor cells, a recent high-resolution study using single-cell RNA sequencing (RNA-seq) of melanoma specimens demonstrated CCL19 expression in cancer-associated fibroblasts (CAF) and CXCL13 with CD8+ exhausted T cells (46).”
BackgroundSelf-citationSpatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422 · cited 2×
“As PD-1 blockade promotes immune cell infiltration in vivo (13), we also performed singlesample gene set enrichment analysis (ssGSEA) using published immune signatures (37), which revealed enrichment of diverse immune cell populations in a subset of patients (group A) treated with ICB (Fig.”
Method
Research works printed but not linked: 1
- Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207–11. doi: 10.1126/science.aad0095. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
Cited by
Items 301–400 of 589
Balko, J. M., & Sosman, J. A. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1356 · Cited by 17
Challenges and Future Prospects on 3D in-vitro Modeling of the Neuromuscular Circuit
Badiola-Mateos, M., Hervera, A., del Río, J. A., & Samitier, J. (2018) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2018.00194 · Cited by 18
“, 2016); (iv) AIM 3D culture chips (AimBiotech, Singapore), employed mostly in cancer-research (Jenkins et al., 2018), although with a great potential to be used in neuromuscular studies, as performed by Uzel et al.”
BackgroundAbdel‐Aziz, A. K., Saadeldin, M. K., D’Amico, P., Orecchioni, S., Bertolini, F., Curigliano, G., & Minucci, S. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.08.013 · Cited by 18
Gundle, K. R., Deutsch, G. B., Goodman, H. J., Pollack, S. M., Thompson, M. J., Davis, J. L., Lee, M.-Y., Ramirez, D. C., Kerwin, W. S., Bertout, J. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0614 · Cited by 19
Ex vivo modeling of precision immuno-oncology responses in lung cancer
Alsaed, B., Smolander, J., Laitinen, H. K., Lin, L., Bobik, N., Lahtinen, L., Räsänen, M., Jansouz, S., Peltonen, K., Jokinen, E., et al. (2024) · Science Advances · doi:10.1126/sciadv.adq6830 · Cited by 18
“Recently, organ- on-chip (OOC) systems using tissue fragments have been used to evaluate ICI responses ( 7 ).”
Chen, D., Wang, B., Li, C., Tao, H., Lu, F., Ruan, Z., Zhao, Z., Li, C., Yan, G., Zhang, H., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102239 · Cited by 30
Self-citationVascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer
Campisi, M., Osaki, T., Dryg, I., Stornante, C., Wolff, J., Weirather, J. L., Weaver, N. C., Tarannum, M., Gillanders, I., Bers, A. E., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.02.008 · Cited by 19
Self-citationPizzurro, G. A., Liu, C., Bridges, K., Alexander, A. F., Huang, A., Baskaran, J. P., Ramseier, J. Y., Bosenberg, M., Mak, M., & Miller‐Jensen, K. (2021) · Cancers · doi:10.3390/cancers13184579 · Cited by 16
From simplicity to complexity in current melanoma models
Michielon, E., de Gruijl, T. D., & Gibbs, S. (2022) · Experimental Dermatology · doi:10.1111/exd.14675 · Cited by 19
King, D. A., Smith, A. R., Pineda, G., Nakano, M., Michelini, F., Goedegebuure, S. P., Thyparambil, S. P., Liao, W., McCormick, A. K., Ju, J., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.21.00489 · Cited by 18
Turpin, R., Liu, R., Munne, P., Peura, A., Rannikko, J. H., Philips, G., Boeckx, B., Salmelin, N., Hurskainen, E., Suleymanova, I., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008053 · Cited by 20
“Earlier works show that human ex vivo explants from various cancer types retain tumor and stroma components in addition to autologous immune cell populations and can respond to anti-PD-1 depending on the cancer type 35,69,70 .”
BackgroundEstablishment of advanced tumor organoids with emerging innovative technologies
Mao, Y., & Hu, H. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217122 · Cited by 20
Picca, F., Giannotta, C., Tao, J., Giordanengo, L., Munir, H., Botta, V., Merlini, A., Mogavero, A., Garbo, E., Poletto, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910823 · Cited by 17
Li, Y., Fan, H., Ding, J., Xu, J., Liu, C., & Wang, H. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.969723 · Cited by 19
“Michna et al. (2018) Modeling lymphatic vessel (LV) Create the lumen structure with primary human lymphatic endothelial cells (HLECs) within collagen hydrogels 3D microfluidic co-culture system The dense ECM promoted LV transformed toward activated phenotype via increasing secretion of IL-6 Lugo-Cintron et al. (2020b)…”
BackgroundMethodInfluentialZhang, W., & Zheng, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1122322 · Cited by 16
“This is a PDO model with significant clinical translational potential to simulate tumor response to CAR-T cell immunotherapy (64).”
MethodModeling immunity in microphysiological systems
Kwee, B. J., Li, X., Nguyen, X.-X., Campagna, C., Lam, J., & Sung, K. E. (2023) · Experimental Biology and Medicine · doi:10.1177/15353702231215897 · Cited by 16
“114 The researchers were able to recapitulate in vivo -like responses of the various tumors to PD-1 blockade via cytokine profiling toward the identification of methods to combat drug resistance.”
BackgroundGao, B. X., Wu, X., Bu, L., Jiang, Q., Wang, L., Liu, H., Zhang, X., Wu, Y., Li, X., Li, J., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk2285 · Cited by 17
“To this end, the IKBKE inhibitor compound 1 (COMPD1) was used ( 36 ), which substantially inhibited the IKBKE-induced band shift and phosphorylation of FoxA1 (fig.”
Self-citationTargeted immunotherapy and nanomedicine for rhabdomyosarcoma: The way of the future
Morel, V. J., Rössler, J. K., & Bernasconi, M. (2024) · Medicinal Research Reviews · doi:10.1002/med.22059 · Cited by 20
Fernandez, E. G., Mai, W. X., Song, K., Bayley, N. A., Kim, J., Zhu, H., Pioso, M. S., Young, P., Andrasz, C. L., Cadet, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54138-9 · Cited by 22
Self-citationPatient-Derived Organoid Models for NKT Cell-Based Cancer Immunotherapy
Palacios, P. A., Flores, I., Cereceda, L., Otero, F. F., Müller, M., Brebi, P., Contreras, H. R., & Carreño, L. J. (2025) · Cancers · doi:10.3390/cancers17030406 · Cited by 15
“The study demonstrates the capacity of PDOs to retain key immune cell populations, including CD8 + T cells, and their interactions with tumor cells, which are pivotal for evaluating immune checkpoint blockade therapies [112].”
Organoids in cancer therapies: a comprehensive review
Xin-Yi, J., Yan-Ran, W., Pin-Ru, D., Shi-Yi, Q., & Jiang, H. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1607488 · Cited by 19
“Operationally, cell-Matrigel mixtures are injected into the central chamber, while culture media are perfused through adjacent channels (Jenkins et al., 2018).”
Immunotherapy response modeling by ex-vivo organ culture for lung cancer
Kamer, I., Bab-Dinitz, E., Zadok, O., Ofek, E., Gottfried, T., Daniel‐Meshulam, I., Hout‐Siloni, G., Nun, A. B., Barshack, I., Onn, A., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02828-w · Cited by 16
Jurj, A. M., Paşca, S., Braicu, C., Rusu, I., Korban, S. S., & Berindan‐Neagoe, I. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.12.002 · Cited by 17
Human-derived Tumor-On-Chip model to study the heterogeneity of breast cancer tissue
Jeibouei, S., Monfared, A. K., Hojat, A., Aref, A. R., Shams, F., Dolati, M., Moradi, A., Hosseini, M., Javadi, S. M. R., Ajoudanian, M., et al. (2024) · Biomaterials Advances · doi:10.1016/j.bioadv.2024.213915 · Cited by 16
Self-citationDeng, Y., Jin, H., Ning, J., Cui, D., Zhang, M., & Yang, H. (2023) · Molecular Medicine · doi:10.1186/s10020-023-00707-5 · Cited by 14
“IHC was performed according to standard protocol as described by previous study (Jenkins et al. 2018).”
MethodApplication of organoids in precision immunotherapy of lung cancer (Review)
Tian, H., Ren, J., Mou, R., & Jia, Y. (2023) · Oncology Letters · doi:10.3892/ol.2023.14071 · Cited by 16
“Nonetheless, the majority of patients with relatively high MSIs or TMBs fail to respond to immunotherapy or will develop a mechanism for adaptive resistance (7).”
BackgroundTumor organoids in cancer medicine: from model systems to natural compound screening
Cong, R., Lu, C., Li, X., Xu, Z., Wang, Y., & Sun, S. (2025) · Pharmaceutical Biology · doi:10.1080/13880209.2025.2458149 · Cited by 17
“Jenkins et al. (2018) established murine-and patient-derived tumor organoids with autologous immune context to recapitulate sensitivity and resistance to PD-1 blockade.”
Immunogenic Cell Death Inducers in Cancer Immunotherapy to Turn Cold Tumors into Hot Tumors
Lucarini, V., Melaiu, O., Gragera, P., Król, K., Scaldaferri, V., Damiani, V., Ninno, A. D., Nardozi, D., Businaro, L., Masuelli, L., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041613 · Cited by 14
“The immunomodulatory effects of drugs were evaluated with microfluidic devices fabricated from polydimethylsiloxane, a biocompatible silicone elastomer, following a standard replica molding technique [50].”
InfluentialHuang, T. H., Huang, W. T., & Bian, Q. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114222 · Cited by 14
Self-citationA roadmap for translational cancer glycoimmunology at single cell resolution
Peixoto, A., Miranda, A., Santos, L. L., & Ferreira, J. A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02335-z · Cited by 16
Organoids in lung cancer: A teenager with infinite growth potential
Xu, Y., Xin, W., Yan, C., Shi, Y., Li, Y., Hu, Y., & Ying, K. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.08.006 · Cited by 15
Progress and application of lung-on-a-chip for lung cancer
Li, L., Bo, W., Wang, G., Juan, X., Xue, H., & Zhang, H. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1378299 · Cited by 18
“In addition, Russell Jenkins and others adapted a 3D micro fl uidic device to culture patient-derived organotypic tumor spheroids, preserving the immune architecture of the tumor microenvironment, and enabling real-time analysis (Jenkins et al., 2018).”
Self-citationNovel Ex Vivo Models of Epithelial Ovarian Cancer: The Future of Biomarker and Therapeutic Research
Clark, J., Fotopoulou, C., Cunnea, P., & Krell, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.837233 · Cited by 17
Sourcing cells for in vitro models of human vascular barriers of inflammation
McCloskey, M. C., Zhang, V. Z., Ahmad, S. D., Walker, S. N., Romanick, S., Awad, H. A., & McGrath, J. L. (2022) · Frontiers in Medical Technology · doi:10.3389/fmedt.2022.979768 · Cited by 14
Preclinical models for development of immune–oncology therapies
Wang, Y., Shelton, S. E., Kastrunes, G. M., Barbie, D. A., Freeman, G. J., & Marasco, W. A. (2022) · Immuno Oncology Insights · doi:10.18609/ioi.2022.41 · Cited by 18
Self-citationOrganoids as an Enabler of Precision Immuno-Oncology
Zhao, J., Fong, A. S. W., Seow, S. V., & Toh, H. C. (2023) · Cells · doi:10.3390/cells12081165 · Cited by 13
“Targeting TBK1, a kinase with multifaceted functions in innate immunity and cell proliferation, also enhances ICI response, as seen in PDOTS of multiple cancers [140].”
BackgroundResultInfluentialPSGL-1 Blockade Induces Classical Activation of Human Tumor-associated Macrophages
Kauffman, K. J., Manfra, D. J., Nowakowska, D., Zafari, M. R., Nguyen, P. A., Phennicie, R., Vollmann, E. H., O’Nuallain, B., Basinski, S., Komoroski, V., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0513 · Cited by 13
“Previously, in ex vivo tumor cultures, 30%–50% response in one of the analytes had been shown to correlate with clinical response (40, 41).”
BackgroundAdvances and Challenges in Human 3D Solid Tumor Models
Natesh, N. R., & Varghese, S. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202419912 · Cited by 15
Hong, C., & Lyu, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157247 · Cited by 18
Tumor organoids to study gastroesophageal cancer: a primer
Jin, R. U., & Mills, J. C. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa035 · Cited by 14
“…these murine models of gastroesophageal cancers progress to cancer in a manner that incorporates the precancerous lesions seen in humans, i.e. atrophic gastritis with spas-molytic polypeptide expressing metaplasia (SPEM) and intestinal metaplasia (Correa, 1992 ; Jin and Mills, 2018 , 2019 ).”
BackgroundPilato, M. D., Gao, Y., Sun, Y., Fu, A., Graß, C., Seeholzer, T., Feederle, R., Mazo, I. B., Kazer, S. W., Litchfield, K., et al. (2023) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-22-18 · Cited by 15
“B: Waterfall plots for PDOTS (n ¼ 13, indicated tumor types) treated with aPD-1 (pembrolizumab, 250 lg/mL), (S)-mepazine (MPT-0308 or MPT0118, 3–5 lM), or both showing percentage change in cell viability relative to untreated control.”
InfluentialSelf-citationYang, Z., Yu, J. Q., & Wong, C. C. (2024) · Cells · doi:10.3390/cells13161312 · Cited by 13
“…used for conventional and targeted chemotherapeutics screening, but they are also viable platforms for evaluating immune therapy efficacy, such as PD-1 blockade therapy [67,95] and combination therapy (such as the combination of immune checkpoint inhibitors and angiogenesis inhibitors) [96,97].”
BackgroundKim, H. J., Kim, H., Kim, S., Roh, J., Yun, J. H., & Kim, C. (2025) · Autophagy · doi:10.1080/15548627.2025.2481661 · Cited by 14
“Targeting TBK1 boosted the efficacy of immune checkpoint blockade in murine-and patient-derived organo-typic tumor spheroids [79,93].”
Eguren‐Santamaría, I., Melero, I., Rodríguez, I., Ortego, I., Armero, M., Gálvez‐Cancino, F., López‐Janeiro, Á., de Andrea, C. E., & Sanmamed, M. F. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011279 · Cited by 18
“38 Regarding tumor-cell killing, evidence of an association between ex vivo and clinical responses remains limited to short series of cultures derived from anti- PD- 1-resistant melanomas.”
InfluentialPatient-derived model systems and the development of next-generation anticancer therapeutics
Krall, N., Superti‐Furga, G., & Vladimer, G. I. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.01.002 · Cited by 12
Pyo, D. H., Hong, H. K., Lee, W. Y., & Cho, Y. B. (2020) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1738907 · Cited by 13
“key features of the TME can be used to effectively evaluate responses to immunotherapeutic agents such as immune checkpoint blockade.(15) Furthermore, the organoids or organotypic tumor spheroids model can be used as a drug screening platform.”
BackgroundMethodInfluentialThe future of microfluidics in immune checkpoint blockade
Briones, J., Espulgar, W. V., Koyama, S., Takamatsu, H., Tamiya, E., & Saito, M. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-00248-7 · Cited by 13
“The results showed that DN cells supports antitumor activity of the ex vivo checkpoint blockade [63, 64, 66].”
BackgroundVarrone, F., Mandrich, L., & Caputo, E. (2021) · Cancers · doi:10.3390/cancers13225788 · Cited by 13
“In particular, patient- and murine-derived tumor spheroids (MDOTS/PDOTS), retaining tumor-infiltrating lymphoid and myeloid subpopulations, were generated and then used in short-term ex vivo culture to analyze their response to PD-1 blockade treatment, by profiling the secreted cytokines upon ICB treatment [147].”
BackgroundMethodSun, Y., Tang, H., Wang, X., Fěng, F., Fan, T., Zhao, D., Xiong, B., Xie, H., & Liu, T. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2076674 · Cited by 13
Targeting the Cbl-b-Notch1 axis as a novel immunotherapeutic strategy to boost CD8+ T-cell responses
Monticone, G., Csibi, F., Leit, S. M., Ciccone, D. N., Champhekar, A. S., Austin, J. E., Ucar-Bilyeu, D. A., Hossain, F., Huang, Z., Ibba, S. V., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.987298 · Cited by 13
“Tumor-derived organoids are clusters of cells which contain all cell types present in the original tumor, including cancer cells, infiltrating immune cells and stroma cells and are a reliable ex vivo system that recapitulates the features of the original tumor and its microenvironment (46, 47).”
BackgroundShen, L., Huang, H., Wei, Z., Chen, W., Li, J., Yao, Y., Zhou, J., Liu, J., Sun, S., Xia, W., et al. (2023) · MedComm · doi:10.1002/mco2.433 · Cited by 12
“In recent years, researchers have employed in vitro organoid models to evaluate drug sensitivity towards immunotherapy, 51,54 which turned out that EVs are greatly involved.”
BackgroundSelf-citationAksoy, S. A., Earl, J., Grahovac, J., Karakaş, D., Lencioni, G., Sığırlı, S., & Bijlsma, M. F. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.12.003 · Cited by 12
Models for Monocytic Cells in the Tumor Microenvironment
Lee, S. W. L., Adriani, G., Kamm, R. D., & Gillrie, M. R. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-35723-8_7 · Cited by 12
Self-citationUncovering Pharmacological Opportunities for Cancer Stem Cells—A Systems Biology View
Correia, C., Weisskittel, T., Ung, C. Y., Villasboas, J. C., Billadeau, D. D., Kaufmann, S. H., & Li, H. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.752326 · Cited by 11
“…devices, as well as the development of humanized mouse models or explant 3D cultures model (patient- or mousederived tumor spheroids) (Sanmamed and Chen, 2014; Zitvogel et al., 2016; Jenkins et al., 2018; Vunjak-Novakovic et al., 2021), can provide an excellent opportunity to bridge this gap.”
BackgroundLockhart, E. J., Horowitz, L. F., Rodriguez, A. D., Zhu, S., Nguyen, T., Mehrabi, M., Gujral, T. S., & Folch, A. (2024) · Lab on a Chip · doi:10.1039/d4lc00016a · Cited by 11
Smalley, M., Przedborski, M., Thiyagarajan, S., Pellowe, M., Verma, A., Brijwani, N., Datta, D., Jain, M., Shanthappa, B., Kapoor, V., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101229 · Cited by 12
Jain, K. K. (2020) · Springer eBooks · doi:10.1007/978-3-030-62080-6_20 · Cited by 13
Current and Prospective Methods for Assessing Anti-Tumor Immunity in Colorectal Cancer
Nussbaum, Y. I., Manjunath, Y., Suvilesh, K. N., Warren, W. C., Shyu, C., Kaifi, J. T., Ciorba, M. A., & Mitchem, J. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094802 · Cited by 12
“In these systems, IFC can also be used to measure cell proliferation and death [33,34].”
MethodKim, S., Yun, S., Doh, J., & Kim, H. N. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400475 · Cited by 13
Applications and evolution of 3D cancer-immune cell models
Co, I. L., Fomina, A., Nurse, M., & McGuigan, A. P. (2024) · Trends in biotechnology · doi:10.1016/j.tibtech.2024.06.008 · Cited by 13
TBK1-Zyxin signaling controls tumor-associated macrophage recruitment to mitigate antitumor immunity
Zhou, R., Wang, M., Li, X., Liu, Y., Yao, Y., Wang, A., Chen, C., Zhang, Q. Y., Wu, Q., Zhang, Q., et al. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00244-9 · Cited by 11
“Research indicates that inhibiting TBK1 can enhance antitumor immunity (Jenkins et al, 2018; Sun et al, 2023; Xiao et al, 2017), but more comprehensive studies are needed to understand these potential mechanisms.”
Lizana‐Vasquez, G. D., Ramasubramanian, S., Davarzani, A., Cappabianca, D., Saha, K., Karumbaiah, L., & Torres‐Lugo, M. (2024) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.37823 · Cited by 11
Turpin, R., Peltonen, K., Rannikko, J. H., Liu, R., Kumari, A. N., Nicorici, D., Lee, M. H., Mutka, M., Kovanen, P. E., Niinikoski, L., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2466305 · Cited by 14
“Human ex vivo tumor models have been used to dissect early immunotherapy responses 2–4 with promising predictive potential for patients receiving immune-checkpoint blockade (ICB) therapy 2 .”
BackgroundMoresi, F., Noto, F., Vasudevan, J., Bisteau, X., Adriani, G., & Pavesi, A. (2025) · Advanced Therapeutics · doi:10.1002/adtp.202500098 · Cited by 13
Tumor immune organoids in immunotherapy resistance and drug screening
Zhang, M., Li, L., Pu, H., Yan, W., Zhang, X., Guo, X., Zhao, Y., Meng, Q., & Yin, M. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101360 · Cited by 12
Doty, D. T., Schüler, J. B., Mott, V. L., Bryan, C. M., Moore, N. F., Ho, J. C., & Borenstein, J. T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186478 · Cited by 12
“Many of these developments involve two-dimensional culturing of cancer cell lines, suspended spheroid systems, and organoids cultured in extracellular matrix [14] for the purposes of drug screening [15,16] and elucidating the mechanisms involved in the immune checkpoint blockade [17,18].”
BackgroundMethodPatient-Derived In Vitro and In Vivo Models of Cancer
Claridge, S. E., Cavallo, J., & Hopkins, B. D. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-91836-1_12 · Cited by 11
Xue, B., Schüler, J. B., Harrod, C. M., Lashuk, K., Bomya, Z., & Hribar, K. C. (2023) · Cells · doi:10.3390/cells12081145 · Cited by 14
Nguyen, A., Ramesh, A., Fish, A., & Kulkarni, A. A. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202400393 · Cited by 10
Wichroski, M. J., Liu, S.-Q., Zasadil, L. M., Benci, J. L., Gedeon, P. C., Condon, K. J., Joshi, S., Posy, S., Carlson, P., Maier, A., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0156 · Cited by 10
“Using NSCLC PDOTSs (27, 28), we showed that BMS-986408/nivo-lumab combination therapy improved both the depth and breadth of T-cell cytokine responses compared with either monotherapy.”
Self-citationApplication of microfluidic technology in cancer research and therapy
Azadi, S., Es, H. A., Kulasinghe, A., Bordhan, P., & Warkiani, M. E. (2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2020.02.012 · Cited by 12
Future perspectives from lung cancer pre-clinical models: new treatments are coming?
Bersani, F., Morena, D., Picca, F., Morotti, A., Tabbò, F., Bironzo, P., Righi, L., & Taulli, R. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-189 · Cited by 10
“This technology is particularly powerful to interrogate the tumor immune microenvironment, specific cell-cell interactions as well as vasculogenesis, angiogenesis, blood-brain barrier and migration/metastasis assays in a spatiotemporal setting that can mimic in vivo conditions more accurately (125,132-134).”
BackgroundGuzzeloni, V., Veschini, L., Pedica, F., Ferrero, E., & Ferrarini, M. (2022) · Antibodies · doi:10.3390/antib11030046 · Cited by 13
Evaluation of PD-1 blockade using a multicellular tumor spheroid model.
Zhou, S., Zhu, M., Meng, F., Shao, J., Xu, Q., Wei, J., & Liu, B. (2019) · Europe PMC (PubMed Central) · Cited by 13
Saha, T., van Vliet, A. A., Cui, C., Jimenez-Macias, J. L., Kulkarni, A., Pham, L. N., Lawler, S. E., Spanholtz, J., Georgoudaki, A., Duru, A. D., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.754443 · Cited by 11
“activity of aNK cells in GBM, we first deployed a 3D microfluidic tissue culture platform which leverages collagen matrices and tumor spheroids that facilitate ex vivo testing of anticancer drugs (Jenkins et al., 2018).”
MethodInfluentialHuman Colon Organoids and Other Laboratory Strategies to Enhance Patient Treatment Selection
Johnson, K. A., DeStefanis, R. A., Emmerich, P. B., Grogan, P. T., Kratz, J. D., Makkar, S. K., Clipson, L. J., & Deming, D. A. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00737-9 · Cited by 13
Molecular Targeted Radiosensitizers: Opportunities and ChallengesPreprint
Willers, H., & Eke, I. (2020) · doi:10.31219/osf.io/k9bfx · Cited by 10
The applications and techniques of organoids in head and neck cancer therapy
Hao, Q., Tan, X., Zhang, W., Zhou, Y., Chen, S., Zha, D., Wang, S., & Wen, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1191614 · Cited by 11
“Well-designed microfluidic devices that maintain autologous myeloid and lymphoid cell populations similar to the original donor can be used to detect dynamic response and resistance to immune checkpoint inhibitors (85).”
BackgroundKnockout cancer by nano-delivered immunotherapy using perfusion-aided scaffold-based tumor-on-a-chip
Suryavanshi, P., & Bodas, D. (2024) · Nanotheranostics · doi:10.7150/ntno.87818 · Cited by 9
Mazzaglia, C., Huang, Y. Y. S., & Shields, J. D. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115485 · Cited by 10
Wang, Y., Sun, X. Y., Lu, B., Zhang, D., Yin, Y., Liu, S., Chen, L., & Zhang, Z. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177368 · Cited by 10
Sullivan, R. J., Cillo, A. R., Ferris, R. L., Jenkins, R. W., Kluger, H. M., Kok, M., Lipson, E. J., Paruzzo, L., Redmond, W. L., Ruella, M., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011929 · Cited by 11
Self-citationOrganoid: a promising solution to current challenges in cancer immunotherapy
Kang, X., Cheemalamarri, S. K., & Yin, Q. (2025) · npj Biomedical Innovations. · doi:10.1038/s44385-025-00051-9 · Cited by 9
“Mechanistic studies using organoids have play a critical role in investigating signaling pathways of immunotherapies for therapeutic prediction 179 .”
Microfluidic systems to study tissue barriers to immunotherapy
Ramirez, A., Amosu, M., Lee, P. M. Y., & Maisel, K. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01016-2 · Cited by 10
“They consistently observed more cytokine production, including CCL19 and CXC13 in tumor spheroids with phenotypically immunosuppressed infiltrating lymphocytes [58].”
BackgroundHu, L., Zhang, Y., Guo, L., Zhong, H., Xie, L., Zhou, J. R., Liao, C., Yao, H., Fang, J. Q., Liu, H., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2023.12.010 · Cited by 10
Self-citationBBOX1 restrains TBK1-mTORC1 oncogenic signaling in clear cell renal cell carcinoma
Liao, C., Hu, L., Jia, L., Zhou, J. R., Wang, T., Kim, K., Zhong, H., Yao, H., Dong, L., Guo, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56955-y · Cited by 11
Self-citationMacrophage sensitivity to bexmarilimab-induced reprogramming is shaped by the tumor microenvironment
Rannikko, J. H., Turpin, R., Boström, P., Virtakoivu, R., Harth, C., Takeda, A., Tamminen, A., Koskivuo, I., & Hollmén, M. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011292 · Cited by 14
Song, S., Li, B., Carvalho, M. R., Wang, H., Mao, D., Wei, J., Chen, W., Weng, Z.-H., Chen, Y., Deng, C., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108276 · Cited by 11
An overview of immunotoxicity in drug discovery and development
Nandre, R. M., & Terse, P. (2024) · Toxicology Letters · doi:10.1016/j.toxlet.2024.11.007 · Cited by 9
Deciphering Breast Tumor Heterogeneity Through Patient-Derived Organoids and Circulating Tumor Cells
Policastro, B., Nissen, N., & Alves, C. L. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15070271 · Cited by 8
“…first culturing minced tumor tissue in low-attachment plates to form spheroids, which are then transferred to a microfluidic device with controlled flow and regulated concentrations of gel and media through microchannels to provide a stable and dynamic environment for the spheroids [42,43].”
Organoid-based precision cancer modeling: New frontier in lung cancer research
Terai, H., Yasuda, H., & Sato, T. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116595 · Cited by 10
Shukla, A. K., Shukla, S., Suryawanshi, S. P., Upadhyay, A. M., Ray, N., Thiruppathi, G., Dutta, S. D., & Mongre, R. K. (2025) · Current Oncology · doi:10.3390/curroncol32120653 · Cited by 10
Guerrero‐López, P., Alamán‐Díez, P., Hernández-Hatibi, S., Balsas, P., & Garcia-Aznar, J. M. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115836 · Cited by 9
Tsukamoto, Y., Hirashita, Y., Shibata, T., Fumoto, S., Kurogi, S., Nakada, C., Kinoshita, K., Fuchino, T., Murakami, K., Inomata, M., et al. (2023) · Cancers · doi:10.3390/cancers15164104 · Cited by 10
“Particularly, organ-on-chip-based functional testing for immune-checkpoint inhibitors involving co-culture with immune cells [27] is being developed.”
Zhao, Z., Zhang, S., Jiang, N., Zhu, W., Song, D., Liu, S., Yu, W., Bai, Y., Zhang, Y., Wang, X., et al. (2024) · Angewandte Chemie · doi:10.1002/ange.202317613 · Cited by 13
STING is crucial for the survival of RUNX1::RUNX1T1 leukemia cells
Sun, Y., Wu, Y., Pang, G.-Z., Huang, J., Sheng, M., Xie, J., Chen, P., Wang, Y., Yin, D., Zhao, G., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02383-8 · Cited by 9
Low-cost robotic manipulation of live microtissues for cancer drug testing
Stepanov, I., Gottshall, N. R., Ahmadianyazdi, A., Sinha, D., Lockhart, E. J., Nguyen, T. N. H., Hassan, S., Horowitz, L. F., Yeung, R. S. W., Gujral, T. S., et al. (2025) · Science Advances · doi:10.1126/sciadv.ads1631 · Cited by 11
Bionanotechnology and bioMEMS (BNM): state-of-the-art applications, opportunities, and challenges
Borenstein, J. T., Cummins, G., Dutta, A., Hamad, E. M., Hughes, M. P., Jiang, X., Lee, H., Lei, K. F., Tang, X. S., Zheng, Y., et al. (2023) · Lab on a Chip · doi:10.1039/d3lc00296a · Cited by 10
Studying TCR T cell anti-tumor activity in a microfluidic intrahepatic tumor model
Adriani, G., Pavesi, A., & Kamm, R. D. (2018) · Methods in cell biology · doi:10.1016/bs.mcb.2018.05.009 · Cited by 10
Self-citationState of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era
Bakouny, Z., Flippot, R., Braun, D. A., Lalani, A. A., & Choueiri, T. K. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.02.014 · Cited by 8
Metadata
- Authors
- Jenkins, R. W., Aref, A. R., Lizotte, P. H., Ivanova, E., Stinson, S., Zhou, C. W., Bowden, M., Deng, J., Liu, H., Miao, D., He, M. X., Walker, W., Zhang, G., Tian, T., Cheng, C., Wei, Z., Palakurthi, S., Bittinger, M., Vitzthum, H., Kim, J. W., Merlino, A., Quinn, M., Venkataramani, C., Kaplan, J. A., Portell, A., Gokhale, P. C., Phillips, B., Smart, A., Rotem, A., Jones, R. E., Keogh, L., Anguiano, M., Stapleton, L., Jia, Z., Barzily-Rokni, M., Cañadas, I., Thai, T. C., Hammond, M. R., Vlahos, R., Wang, E. S., Zhang, H., Li, S., Hanna, G. J., Huang, W., Hoang, M. P., Piris, A., Eliane, J.-P., Stemmer-Rachamimov, A. O., Cameron, L., Su, M.-J., Shah, P., Izar, B., Thakuria, M., LeBoeuf, N. R., Rabinowits, G., Gunda, V., Parangi, S., Cleary, J. M., Miller, B. C., Kitajima, S., Thummalapalli, R., Miao, B., Barbie, T. U., Sivathanu, V., Wong, J., Richards, W. G., Bueno, R., Yoon, C. H., Miret, J., Herlyn, M., Garraway, L. A., Van Allen, E. M., Freeman, G. J., Kirschmeier, P. T., Lorch, J. H., Ott, P. A., Hodi, F. S., Flaherty, K. T., Kamm, R. D., Boland, G. M., Wong, K.-K., Dornan, D., Paweletz, C. P., & Barbie, D. A.
- Affiliations
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Gilead Sciences (United States) (US)
- Broad Institute (US)
- The Wistar Institute (US)
- New Jersey Institute of Technology (US)
- 11Center for Applied Medical Research, University of Navarra, Pamplona, Spain.
- Brigham and Women's Hospital (US)
- Massachusetts Institute of Technology (US)
- 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Corresponding author
- Dornan, David
- Barbie, David A.
- ORCID
- Jenkins, Russell W.
- Aref, Amir R.
- Lizotte, Patrick H.
- Ivanova, Elena
- Zhou, Chensheng W.
- Bowden, Michaela
- Deng, Jiehui
- Liu, Hongye
- Miao, Diana
- He, Meng Xiao
- Zhang, Gao
- Tian, Tian
- Cheng, Chaoran
- Wei, Zhi
- Palakurthi, Sangeetha
- Portell, Andrew
- Gokhale, Prafulla C.
- Smart, Alicia
- Rotem, Asaf
- Jones, Robert E.
- Keogh, Lauren
- Jia, Zhiheng
- Barzily-Rokni, Michal
- Cañadas, Israel
- Thai, Tran C.
- Wang, Eric S.
- Zhang, Hua
- Li, Shuai
- Hanna, Glenn J.
- Huang, Wei
- Hoang, Mai P.
- Piris, Adriano
- Stemmer-Rachamimov, Anat O.
- Cameron, Lisa
- Shah, Parin
- Izar, Benjamin
- Thakuria, Manisha
- LeBoeuf, Nicole R.
- Rabinowits, Guilherme
- Parangi, Sareh
- Cleary, James M.
- Miller, Brian C.
- Kitajima, Shunsuke
- Thummalapalli, Rohit
- Barbie, Thanh U.
- Wong, Joshua
- Richards, William G.
- Bueno, Raphael
- Yoon, Charles H.
- Miret, Juan
- Herlyn, Meenhard
- Garraway, Levi A.
- Freeman, Gordon J.
- Lorch, Jochen H.
- Ott, Patrick A.
- Hodi, F. Stephen
- Flaherty, Keith T.
- Kamm, Roger D.
- Boland, Genevieve M.
- Wong, Kwok-Kin
- Paweletz, Cloud Peter
- Barbie, David A.
- Venue
- Cancer Discovery
- Published
- 2018-02-01
- Volume
- 8
- Issue
- 2
- Pages
- 196-215
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5809290
- OpenAlex
- W2766123339
- Cited by
- 594
- References
- 62
- Citations by year
- 2026: 67 · 2025: 76 · 2024: 91 · 2023: 73 · 2022: 76 · 2021: 73 · 2020: 72 · 2019: 37 · 2018: 28
- FWCI
- 16.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- HHS | NIH | National Cancer Institute (NCI) (NCI T32 CA009172-41, 1R01CA149738-01, NCI-R01 CA190394-01, P01CA120964, 5R01CA163896-04, 5R01CA140594-07, 5R01CA122794-10, 5R01CA166480-04)
- SU2C (SU2C-AACR-DT17-15)
- HHS | NIH | National Institute of General Medical Sciences (NIGMS) (NIGMS T32 GM008313)
- National Science Foundation (NSF) (NSF GRFP DGE1144152)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- anti-PD-1 therapy, immune checkpoint blockade, tumor microenvironment, immunotherapy resistance, cytokine production, precision immuno-oncology, combination therapy, microfluidic culture, patient-derived tumor models
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Flow Cytometry, Humans, Immunohistochemistry, Tumor Cells, Cultured, Immunophenotyping, Cytokines, Spheroids, Cellular, Cell Culture Techniques, Drug Resistance, Neoplasm, Cell Line, Tumor, Microfluidic Analytical Techniques, Mice, Time-Lapse Imaging, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.